<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03323879</url>
  </required_header>
  <id_info>
    <org_study_id>DELIGHT</org_study_id>
    <nct_id>NCT03323879</nct_id>
  </id_info>
  <brief_title>Combined LDR Boost and HDR Whole Gland</brief_title>
  <acronym>Delight</acronym>
  <official_title>Dominant Intraprostatic Lesion Boost With Focused LDR Brachytherapy (BT) Integrated to Whole Prostate HDR BT: Safety and Feasibility Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose finding Phase I/II study of combined focused LDR brachytherapy boost with
      whole gland single fraction HDR for men with low and intermediate risk prostate cancer and
      Dominant Intraprostatic Lesion (DIL) visible on multi parametric MRI. Patients will receive
      19 Gy HDR to the whole gland with concurrent LDR brachytherapy boost to the DIL, in a
      sequential dose escalation manner. Primary endpoints are early toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will have low and intermediate risk prostate cancer with a dominant
      intraprostatic lesion definable on multi parametric MRI (PIRADS 4 or 5). Patients will have
      MR planned LDR focal brachytherapy to the DIL using iodine-125, while at the same time have
      single 19 Gy delivered to the whole prostate using ultrasound directed high dose-rate
      brachytherapy (HDR). The LDR boost dose will start at 50 Gy, and increase DIL dose in
      sequential cohorts of patients up until a dose of 80 Gy. Up to 20 patients will be included.
      Primary endpoint is toxicity at 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential dose escalation design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute urinary and rectal toxicity at 3 months as measured using NCI CTCAE v 4.0</measure>
    <time_frame>At 3 months</time_frame>
    <description>Acute urinary and rectal toxicity within the first 3 months as measured using NCI CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late urinary and rectal toxicity using NCI CTCAE v4.0</measure>
    <time_frame>3-montly for first year, then 6-monthly until Year 5</time_frame>
    <description>Cumulative incidence of urinary and rectal toxicity beyond 3 months using NCI CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (HRQOL) changes</measure>
    <time_frame>3 monthly for first year, then annually year 1-5</time_frame>
    <description>Changes in HRQOL as assessed using Expanded Prostate Index Composite (EPIC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>will be reported at 5 years</time_frame>
    <description>biochemical disease-free survival using PSA nadir + 2 ng/ml definition (Phoenix)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Carcinoma Prostate</condition>
  <arm_group>
    <arm_group_label>LDR/HDR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI planned LDR boost to DIL with concurrent whole gland 19 Gy HDR. LDR dose will be sequentially escalated from 50 Gy to 80 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>LDR/HDR</intervention_name>
    <description>Focal LDR to dominant lesion with whole gland 19 Gy HDR</description>
    <arm_group_label>LDR/HDR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed Adenocarcinoma of the prostate

          -  Single PIRADS 4 or 5 lesion on multiparametric MRI

          -  T1c-T2b on rectal exam

          -  Gleason 3+3 and PSA &lt; 20ng/mL

          -  Gleason 3+4 and PSA &lt;10ng/mL

          -  Less than 50% of the cores positive in an untargeted prostate biopsy.

          -  Prostate volume &lt; 60 cc

        Exclusion Criteria:

          -  Incapable or ineligible for MRI imaging

          -  Previous trans-urethral resection of prostate (TURP)

          -  Previous or current use of androgen deprivation

          -  Baseline International Prostate Symptom Score (IPSS) &gt; 15

          -  Evidence of distant or nodal metastasis

          -  Disease that contraindicates treatment with radiation (e.g connective tissue disease)

          -  Unsuitable for anesthesia due to comorbidity
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gerard C Morton, MD</last_name>
    <phone>4164806165</phone>
    <email>Gerard.Morton@sunnybrook.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunnybrook Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard C Morton, MD</last_name>
      <phone>4164806165</phone>
      <email>Gerard.Morton@sunnybrook.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brachytherapy</keyword>
  <keyword>LDR</keyword>
  <keyword>HDR</keyword>
  <keyword>monotherapy</keyword>
  <keyword>focal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

